Results 241 to 250 of about 19,218 (261)
Some of the next articles are maybe not open access.
Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma
Dermatology, 2021<b><i>Background:</i></b> Vismodegib has shown clinical efficacy in the management of locally advanced basal cell carcinomas (laBCC). However, non-response to vismodegib is observed in 2–13.5% of patients in clinical studies. The purpose of this study was to identify factors associated with non-response to vismodegib in patients
Hélène Marescassier +8 more
openaire +4 more sources
American Journal of Ophthalmology, 2015
To review our experience treating patients with the Hedgehog pathway inhibitor, vismodegib, in patients with orbital or periocular locally advanced or metastatic basal cell carcinoma (BCC) or basal cell nevus syndrome.Retrospective interventional case series.We reviewed all patients with locally advanced or metastatic orbital or periocular BCC or basal
Omar K. Ozgur +8 more
openaire +2 more sources
To review our experience treating patients with the Hedgehog pathway inhibitor, vismodegib, in patients with orbital or periocular locally advanced or metastatic basal cell carcinoma (BCC) or basal cell nevus syndrome.Retrospective interventional case series.We reviewed all patients with locally advanced or metastatic orbital or periocular BCC or basal
Omar K. Ozgur +8 more
openaire +2 more sources
Treatment of locally advanced basal cell carcinoma with vismodegib
Medicina Clínica (English Edition), 2023Noelia, Moreiras Arias +2 more
openaire +2 more sources
Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose
CutisBasal cell carcinoma (BCC) is the most common cancer in the world, and its incidence continues to rise. Known risk factors for BCC include chronic UV exposure, advanced age, and genetic predisposition. A large majority of BCC cases have an altered Hedgehog (Hh) signaling pathway.
Evan, Mak, Shannon, Buck
openaire +2 more sources
Drugs, 2012
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
openaire +2 more sources
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
openaire +2 more sources
Severe Necrotizing Locally Advanced Basal Cell Carcinoma With Osteomyelitis
Advances in Skin & Wound CareLocally advanced basal cell carcinoma (BCC) is an uncommon and complex presentation of BCC. These tumors can present as extensive nonhealing ulcers and require skin biopsy to rule out other causes, including malignant, infectious, and inflammatory etiologies.
Anjie Ge +3 more
openaire +1 more source
Locally advanced basal cell carcinoma associated with distinct gut microbiome signature
JDDG: Journal der Deutschen Dermatologischen GesellschaftClinical letter.
Oscar M. Moreno‐Arrones +7 more
openaire +3 more sources
Neoadjuvant Sonidegib for the Management of Locally Advanced Basal Cell Carcinoma: A Case Report
Journal of Drugs in DermatologyNeoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia).
Carmen, Hollield +3 more
openaire +2 more sources
Vismodegib in treatment of reccurence, locally advanced basal cell carcinoma
Onkologie, 2021Simona Michalčová, Hana Mičaníková
openaire +1 more source